Quince Therapeutics, Inc. (CRTX) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
	10-K	10-K	10-K	10-K	10-K	S-1/A
Revenues	0.0	0.0	0.0	0.0	0.0	9.1
Revenue growth					-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	10.4
Gross profit	0.0	0.0	0.0	0.0	0.0	-1.3
Gross margin						-14.0%
Selling, general and administrative [+]	26.0	29.5	17.6	9.0	2.0	1.3
General and administrative	26.0	29.5	17.6	9.0	2.0	1.3
Research and development	25.2	60.8	61.3	30.2	10.1
Other operating expenses						7.8
EBITDA [+]	-51.0	-90.0	-78.6	-39.0	-12.1	-10.3
EBITDA growth	-43.3%	14.5%	101.5%	223.0%	16.9%
EBITDA margin						-113.5%
Depreciation and amortization	0.2	0.3	0.3	0.2	0.1	0.0
EBIT [+]	-51.2	-90.3	-78.9	-39.2	-12.1	-10.4
EBIT growth	-43.3%	14.5%	101.4%	223.2%	16.9%
EBIT margin						-114.0%
Non-recurring items [+]	0.8
Asset impairment	0.8
Interest income, net [+]	1.1	0.6	2.0	2.2	-0.2	-1.6
Interest expense					1.0	1.6
Interest income	1.1	0.6	2.0	2.2	0.8
Other income (expense), net [+]	-1.0	-0.2			-0.2	-0.2
Unrealized gain/loss on derivatives						-0.2
Other	-1.0	-0.2
Pre-tax income	-51.9	-89.9	-76.8	-37.0	-12.5	-12.2
Income taxes	0.3	0.0	0.0	0.0	0.0	0.0
Tax rate		0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-51.9	0.0	-76.8	-37.0	-12.5	-12.2
Net margin						-134.5%

Basic EPS [+]	($1.55)	$0.00	($2.63)	($1.94)	($3.71)	($3.70)
Growth		-100.0%	35.6%	-47.6%	0.2%
Diluted EPS [+]	($1.55)	$0.00	($2.63)	($1.94)	($3.71)	($3.70)
Growth		-100.0%	35.6%	-47.6%	0.2%

Shares outstanding (basic) [+]	33.5	29.7	29.2	19.0	3.4	3.3
Growth	12.7%	1.9%	53.3%	466.1%	1.8%
Shares outstanding (diluted) [+]	33.5	29.7	29.2	19.0	3.4	3.3
Growth	12.7%	1.9%	53.3%	466.1%	1.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.